SHANGHAI - Dec. 2rd, 2009 -- HD Biosciences (China) Co., Ltd. (HDB), a Shanghai-based biotechnology company specializing in high value drug discovery contract research services. During a site visit to HDB, Pfizer Lo Jolla site visitor presented to Dr. Baiqiu Wang, Head of Enzyme Group in HDB, the award of “Difference Maker” for her great contribution in one of the research collaborations.

"Baiqiu led a team of scientists at HDB who has made one of the most successfully projects at a Chinese CRO to date. She is an effective leader and communicator and has consistently demonstrated a strong customer focus in her interactions with Lo Jolla project team”, quoted from the Pfizer Lo Jolla project team, “Under Baiqiu's leadership, HDB has been delivering quality and timely data.” Baiqiu's work greatly helped Pfizer team improve the study quality with significant reduction of cost.

"The Pfizer team has been extremely satisfied with HDB's accomplishment and Baiqiu's outstanding performance and it is all of us, through our hard working, made HDB a difference” proudly commented by Dr. Xuehai Tan, CEO and president of HDB.

About HD Biosciences (China) Co. Ltd.
HD Biosciences Co., Ltd. is a biotechnology company based in Shanghai, China, that specializes in high value drug discovery contract research services. With operation units in Shanghai and Beijing, China, HD Biosciences has experienced and dedicated teams to meet the R&D needs of pharmaceutical and biotechnology companies all over the world. HDB offers a broad range of services in a high-throughput setting for plate-based pharmacology and compound profiling, including but not limited to GPCR, ion channel, kinase profiling, and is expanding to in vitro/in vivo DMPK and animal disease models research areas.

HDB Contact:
Angela Chen,
86-21-51163716
angelachen@hdbiosciences.com